This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35299 ALKERMES PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (I.R.S ...

Core Insights - Alkermes reported a revenue of $306.51 million for the quarter ended March 2025, reflecting a 12.5% decrease year-over-year [1] - The earnings per share (EPS) was $0.13, down from $0.44 in the same quarter last year, indicating a significant decline [1] - The revenue fell short of the Zacks Consensus Estimate of $316.7 million, resulting in a surprise of -3.22% [1] - The company experienced an EPS surprise of -53.57%, with the consensus EPS estimate being $0.28 [1] Revenue Breakdown - Manufacturing and Royalty revenues were reported at $62.02 million, below the five-analyst average estimate of $65.33 million, marking a year-over-year decline of 46.9% [4] - Product sales, net, amounted to $244.49 million, slightly below the estimated $254.16 million, but showed a year-over-year increase of 4.7% [4] - Proprietary Sales for VIVITROL reached $101 million, exceeding the four-analyst average estimate of $98.71 million, with a year-over-year growth of 3.4% [4] - Proprietary Sales for ARISTADA were reported at $73.50 million, below the estimated $78.52 million, reflecting a year-over-year decrease of 6.8% [4] - Proprietary Sales for LYBALVI were $70 million, close to the estimated $70.91 million, showing a year-over-year increase of 22.8% [4] - Key Commercial Product Revenues for VUMERITY were $27.80 million, slightly below the three-analyst average estimate of $27.81 million, with a year-over-year decline of 11.1% [4] Stock Performance - Alkermes shares have returned -11.9% over the past month, contrasting with the Zacks S&P 500 composite's -0.7% change [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]

Alkermes (ALKS) came out with quarterly earnings of $0.13 per share, missing the Zacks Consensus Estimate of $0.28 per share. This compares to earnings of $0.44 per share a year ago. These figures are adjusted for non- recurring items. This quarterly report represents an earnings surprise of -53.57%. A quarter ago, it was expected that this drugmaker would post earnings of $0.81 per share when it actually produced earnings of $1.04, delivering a surprise of 28.40%. What's Next for Alkermes? While Alkermes h ...

First Quarter 2025 Financial Results & Business Update May 1, 2025 Forward-Looking Statements and Non-GAAP Financial Information Certain statements set forth in this presentation constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: Alkermes plc's (the "Company") expectations with respect to its current and future financial, commercial and operating performance, business plans or p ...

Alkermes (ALKS) Q1 2025 Earnings Call May 01, 2025 08:00 AM ET Speaker0 and welcome to Alchemy's First Quarter twenty twenty five Financial Results Conference Call. My name is Maria, and I'll be the operator for today's call. All participant lines will be placed on mute to prevent background Please note that this conference is being recorded. I will now turn the call over to Sandra Khoemps, Senior Vice President of Investor Relations and Corporate Affairs. Sandy, you may now begin. Good morning. Welcome to ...

Exhibit 99.1 Alkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 For Media: Katie Joyce +1 781 249 8927 Alkermes plc Reports First Quarter 2025 Financial Results — First Quarter Revenues of $306.5 Million — — GAAP Net Income of $22.5 Million and Diluted GAAP Earnings per Share of $0.13 — — Company Reiterates 2025 Financial Expectations — DUBLIN, May 1, 2025 — Alkermes plc (Nasdaq: ALKS) today reported financial results for the first quarter of 2025. "Our first quarter financial performance provid ...

—    First Quarter Revenues of $306.5 Million ——    GAAP Net Income of $22.5 Million and Diluted GAAP Earnings per Share of $0.13 ——    Company Reiterates 2025 Financial Expectations —DUBLIN, May 1, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for the first quarter of 2025."Our first quarter financial performance provides a solid foundation to deliver on our financial guidance for the year. We are in a strong position in this dynamic macroeconomic environment and remain ...

DUBLIN, April 17, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Thursday, May 1, 2025 to discuss the company's first quarter financial results.The webcast player and accompanying slides may be accessed on the Investors section of Alkermes' website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. A replay of the webcast w ...

Group 1 - Alkermes plc will participate in a webcast panel discussion on "Development of Orexin Receptor Agonist in Sleep-Wake Disorders" at the 24th Annual Needham Virtual Healthcare Conference on April 9, 2025 [1] - The live webcast will be accessible under the Investors tab on Alkermes' website and will be archived for 14 days [1] Group 2 - Alkermes plc is a global biopharmaceutical company focused on developing innovative medicines in neuroscience [2] - The company has a portfolio of proprietary commercial products for treating alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder [2] - Alkermes has a pipeline of clinical and preclinical candidates for neurological disorders, including narcolepsy and idiopathic hypersomnia [2] - The company is headquartered in Ireland, with additional offices in Massachusetts and a manufacturing facility in Ohio [2]